GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

Slides:

Advertisements

Similar presentations

Copyright © 2015 by the American Osteopathic Association.

Advertisements

Supplemental Digital Content 2

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Volume 15, Issue 1, Pages (January 2007)

Volume 24, Issue 3, Pages (September 2016)

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis. Therapeutic effects of TIP60 allosteric modification in DSS-induced colitis.

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Decreased GLP-1 receptor expression in islets after exposure to high glucose. Decreased GLP-1 receptor expression in islets after exposure to high glucose.

Exogenous CRP administration causes fasting hyperglycemia and hyperinsulinemia without altering body composition. Exogenous CRP administration causes fasting.

1018-NT-β-cell clusters protect mice from STZ-induced diabetes.

NOX-deficient NOD-Ncf1m1J immune system has a reduced capacity to transfer type 1 diabetes (T1D) to immune-deficient hosts. NOX-deficient NOD-Ncf1m1J immune.

Effect of the acute administration of benzylamine plus vanadate on oral glucose tolerance test in STZ-induced diabetic rats. Effect of the acute administration.

Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice. Nrf2−/− mice suffered greater renal damage by STZ compared with Nrf2+/+ mice.

Modulation of insulin sensitivity by IL-6 in mice: A lack of PTP1B prevents chronic effects of IL-6. Modulation of insulin sensitivity by IL-6 in mice:

A single dose of liraglutide (Lira) (7. 5 μg/kg or 0

Glucose tolerance in WT and TRPM2-KO mice.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

ΑGLP-1R−/− mice show glucose intolerance and disturbed glucagon secretion in response to i.p. glucose administration. αGLP-1R−/− mice show glucose intolerance.

T1D is reduced in CT-treated NOD mice.

The effect of VSG on body weight and body fat in GLP-1r KO mice.

T1D is reduced in anti-CD3–treated, CXCL10-deficient RIP-LCMV-GP mice (the numbers in parentheses indicate the number of mice in each group). T1D is reduced.

A: Chemical structure of pterosin A

GLP-1 and gastrin combination therapy increases pancreatic insulin content (A) and β-cell mass (B) in NOD mice. GLP-1 and gastrin combination therapy increases.

Chop deletion preserves β-cell function in P58IPK−/− mice.

Rapid improvement of glucose tolerance induced by PP

Adoptive transfer of purified activated G9Cα−/−

Effect of PEDF+DHA treatment on wound healing in diabetic corneas.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

GLP-1 and gastrin combination therapy induces immunoregulatory cell activity in NOD mice. GLP-1 and gastrin combination therapy induces immunoregulatory.

Atrasentan reduces albuminuria in diabetic apoE KO mice.

Diabetes development in B6.H-2g7/RIP-B7.1 and control mice.

Effect of anandamide on blood glucose clearance and insulin sensitivity. Effect of anandamide on blood glucose clearance and insulin sensitivity. A: Intraperitoneal.

Glucose stimulates GLP-1 secretion from the perfused rat intestine by a dose- and absorption-dependent manner. Glucose stimulates GLP-1 secretion from.

Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance. Mice fed GP-SPI diet show improved fasting glucose and oral glucose tolerance.

Systemic treatment with AMPK activators decreases TRPA1 associated with membrane in DRG neurons of db/db mice. Systemic treatment with AMPK activators.

Effects of Rosi treatment on ASKO mice.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Glucose-stimulated insulin secretion, plasma glucagon levels, and pancreatic hormone contents. Glucose-stimulated insulin secretion, plasma glucagon levels,

Estimated glucose delta values (mmol/L) after glucagon injection (5 µg/kg) in octreotide-treated rats. Estimated glucose delta values (mmol/L) after glucagon.

GTTs and ITTs. A: GTTs of WT (◇), LepTg (♦), Akita (open circles), and LepTg:Akita (closed circles) mice at 8 and 16 weeks of age. GTTs and ITTs. A: GTTs.

High-fat diet–induced glucose intolerance is prevented in ghrelin knockout (Ghr-KO) mice. High-fat diet–induced glucose intolerance is prevented in ghrelin.

Loss of Phb2 in β-cells induces development of diabetes over a 3-week period in β-Phb2−/− mice. Loss of Phb2 in β-cells induces development of diabetes.

Blood glucose levels in chicken embryos.

Mice lacking Y1 receptor in the hematopoietic compartment remain healthy under normal chow feeding conditions. Mice lacking Y1 receptor in the hematopoietic.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Intrathecal injection of Kv4

Serum bicarbonate increased by ≥3, ≥4, and ≥5 mEq/L in 52%, 39%, and 22% of patients, respectively, in the combined TRC101 dose group compared with 6%,

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

A: Probability of SICH by baseline glucose level.

(A) Mean glucose concentrations (standard error) over a 3-hour period in 21 placebo- and 15 pramlintide-treated patients with type 1 diabetes treated for.

mTORC1 is required for malignant transformation in the Eμ-Myc model.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Distribution of daily frequency of BGM

Fig. 1. The HCN channel blocker ivabradine (IVA) is analgesic in a mouse model of type 1 diabetes. The HCN channel blocker ivabradine (IVA) is analgesic.

Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo). Five-day exposure to decitabine (DAC) sensitizes cells to doxorubicin (Doxo).

Impairment of liver function upon treatment with 4D5MOCB-ETA.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

A: Glucose levels during basal-bolus and SSI treatment.

DHA and dietary n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in xenograft models. DHA and dietary n-3 PUFAs inhibit endometrial cancer.

Cumulative mean numbers of confirmed (plasma glucose ≤3

Presentation transcript:

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning 3–6 days after diabetes onset (0 weeks) and for the next 3 weeks, NOD mice were treated with twice-daily intraperitoneal injections of vehicle (n = 6), 10 μg/kg GLP-1 (n = 7), 100 μg/kg GLP-1 (n = 7), 1.5 μg/kg gastrin (n = 4), 10 μg/kg GLP-1 plus 1.5 μg/kg gastrin (n = 6), and 100 μg/kg GLP-1 plus 1.5 μg/kg gastrin (n = 7). Blood glucose concentrations in individual mice are shown during the 3 weeks of treatments and for the additional 5 weeks after treatments were stopped. †Mice with blood glucose levels ≥27.5 mmol/l and losing weight were killed. Shaded bars show the normal range for blood glucose (3.5–6.5 mmol/l). Wilma L. Suarez-Pinzon et al. Diabetes 2008;57:3281-3288 ©2008 by American Diabetes Association